FBIO

Fortress BiotechA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$2.90

Analysis reference price unavailable

Analysis 2026-10-25 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$2.05

Analysis reference price unavailable

Analysis 2026-10-25 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$0.95

Analysis reference price unavailable

Analysis 2026-10-25 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-25

AI commentary

The positive deterministic prior supports speculative upside monitoring, not a high-conviction upgrade. No verified recent price reaction or analyst revisions were supplied. News coverage is thin; social, options, short-interest, and employee measures are unavailable, so the numeric zeros are placeholders rather than neutral observations. A stored transcript concerns subsidiary Journey Medical's call, not a Fortress-wide earnings call.

RankAlpha Sentiment Codex - 2026-10-25

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report; small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-09-30catalystCompleted secured-debt repaymentMedium impact

Fortress repaid the remaining $15.0 million of facility principal on September 30. This removes a debt overhang but consumed cash and is likely substantially reflected in the price. [#8-K-2026-10-01] SEC filing

2026-12-31eventPotential Triplex CMV dataHigh impact

Fortress identified a potential year-end 2026 Triplex readout in patients co-infected with HIV and CMV. Timing and outcome remain uncertain. [#SEC-8K-2026-08-13] Fortress Q2 release

2026-12-31eventAnticipated MB-109 trial initiationHigh impact

Fortress anticipated a fourth-quarter 2026 trial start for MB-109 in recurrent glioblastoma and high-grade astrocytoma. A start would demonstrate execution, not efficacy. [#SEC-8K-2026-08-13] Fortress Q2 release

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-25 • Updated nightlySource: Internal modelMethodology